CN107875191A - It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof - Google Patents
It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof Download PDFInfo
- Publication number
- CN107875191A CN107875191A CN201711081762.9A CN201711081762A CN107875191A CN 107875191 A CN107875191 A CN 107875191A CN 201711081762 A CN201711081762 A CN 201711081762A CN 107875191 A CN107875191 A CN 107875191A
- Authority
- CN
- China
- Prior art keywords
- composition
- part group
- effective part
- liver injury
- medicament toxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The present invention relates to a kind of composition for having and reducing liver injury medicament toxicity, the composition of the reduction liver injury medicament toxicity is made up of following weight parts raw material：1 part of mussot swertia herb effective part group, wherein comprising Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin, the mass ratio of five kinds of compositions is (0.04~0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16), help too 0.01 0.5 parts.Meanwhile the invention also discloses the preparation method of said composition.The present invention adds Tibetan medicine processed product assistant too in mussot swertia herb effective part group, effectively reduces the toxicity of mussot swertia herb effective part group, expands application of the Tibetan medicine assistant too in modern medicines.
Description
Technical field
The present invention relates to pharmaceutical technology field, more particularly to the composition and its formula for reducing liver injury medicament toxicity
Preparation method.
Background technology
Bupleurum scorzonerifoliumWild is gentianaceae plant mussot swertia herb Swertia mussotii Franch. drying herb, is hidden
Transliteration name " mulberry drop ", is commonly called as Swertia mussotii, is Tibetan's conventional folk prescription herbal medicine among the people.With clearing liver cholagogic, move back the effect of all hot.With
It is evident in efficacy in treatment icteric hepatitis.Modern study shows that it is more that Bupleurum scorzonerifoliumWild contains iridoid, Oxoxanthone, triterpene etc.
The other chemical composition of species, wherein iridoid constituents include Swertiamarin, sweroside, gentiamarin etc., and have
Anti-inflammatory, promote the pharmacological activity such as hepatic injury cell repair；Xanthones composition includes mangiferin, swertianolin etc., has and suppresses
Transaminase raises, the pharmacological activity such as anti-hepatitis virus；Triterpenes components include oleanolic acid, ursolic acid etc., have anti-inflammatory, liver protection
Pharmacological activity.This seminar personnel have found that Bupleurum scorzonerifoliumWild effective part group includes Swertiamarin, rough gentian in early-stage Study
5 kinds of bitter glycosides, sweroside, mangiferin, Lutonaretin compositions, pharmacological evaluation prove there is the effect of significant anti-liver injury,
Obtain and authorize patent of invention (CN2007101630978 Tibetan capillary extracts and preparation method thereof, pharmaceutical composition and purposes).
But Bupleurum scorzonerifoliumWild extract toxicity is larger, the bad assurance of effective dose.
Tibetan medicine is helped too, and the abbreviation of Tibetan language " benevolence green grass or young crops Europe Qu Zuozhu admires wooden ", " assistant " is refining, " too " refers to ash, powder, " assistant is too "
Mean and be sintered into ash, be successive dynasties name Tibetan medicine by hypertoxic mercury special processing is processed into it is nontoxic, there is peculiar curative effect
Compound, containing eight gold medals, eight ore deposit compositions, be the indispensable key component of Tibetan medicine jewellery class medicine, not independent patent medicine, coordinate it
Medical instrument plays the role of to reduce toxicity, increase curative effect.
The content of the invention
To solve toxicity problem of the mussot swertia herb effective part group under dosage present in prior art, this hair
Bright purpose is to provide a kind of composition for having and reducing liver injury medicament toxicity and preparation method thereof, by the western river deer bud in river
Dish effective part group has carried out assistant too compatibility, effectively reduces Bupleurum scorzonerifoliumWild effective part group toxicity, makes Bupleurum scorzonerifoliumWild
Effective part group safe handling is guaranteed.
It is a kind of there is the composition for reducing liver injury medicament toxicity, it is characterised in that described with anti-liver injury effect
Pharmaceutical composition, mussot swertia herb effective part group and Zuo Tai are included in its component.
Further, it is described that there is the composition for reducing liver injury medicament toxicity, it is characterised in that to be included in its component by weight
Measure 1 part of the mussot swertia herb effective part group of part, assistant too 0.01-0.5 parts.
Further, it is described that there is the composition for reducing liver injury medicament toxicity, it is characterised in that the mussot swertia herb has
Imitate part group and include five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its mass ratio is
(0.04~0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
The preparation of mussot swertia herb effective part group of the present invention using the present inventor early stage achievement in research, i.e., in
The method of state's patent of invention (CN2007101630978)：
(1) Swertia mussotii medicinal material, crushing or segment are taken, with the 10-15 times of 0-95% measured ethanol water or aqueous acetone solution
Extraction three times, merges extract solution three times, is concentrated under reduced pressure, concentrate is carried out with petroleum ether, chloroform, ethyl acetate and n-butanol successively
Distribution, the distribution number of each organic solvent is 4 times, and each volume is concentrate initial volume.Each solvent distribution that is concentrated under reduced pressure is molten
Liquid, recycling design, obtain each solvent distribution position thick paste；
(2) n-butanol distribution position thick paste is dissolved with appropriate distilled water, is loaded onto the big of the resin material I that has pre-processed
Hole resin column upper end, after adsorbing 4-10 hours, eluted with 5-20BV distilled water with 0.5-2BV/h flow velocity.Then with 0.5-
2BV/h flow velocity linear gradient elution, eluent are 10-95% ethanol water, Fractional Collections eluent, merge 10-
40% ethanol water elutes liquid, is concentrated under reduced pressure into no alcohol taste；
(3) concentrate in step (2) is subjected to second of macroreticular resin post separation, concretely comprises the following steps and be loaded onto concentrate
Resin material II macroporous resin column upper end, 4-10 hours are adsorbed, eluted with distilled water with 0.5-3BV/h flow velocity, eluent
For 3-8BV, with 10-95% ethanol water linear gradient elutions, 10-30% ethanol waters elution liquid is collected, concentrates the receipts
Liquid collecting, it dry, pulverize and produce the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn into packet Swertia mussotii glycosides powder.Institute
It is river of the present invention that the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn, which is stated, into Swertia mussotii glycosides powder is grouped
Western Swertia patens effective part group.
Further, it is described that there is the composition for reducing liver injury medicament toxicity, it is characterised in that Chuan Xi is included in its component
Acceptable carrier or auxiliary material on Swertia patens effective part group, Zuo Tai and medicine.
Further, acceptable carrier or auxiliary material are in conventional disintegrant, filler and lubricant on the medicine
One or more kinds of combinations.
A kind of preparation method with the composition for reducing liver injury medicament toxicity, it is characterised in that comprise the following steps：
D1, assistant is taken first too, fine grinding, weighed by formula；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning by assistant Taihe county mussot swertia herb effective part group after D1 fine grindings with bottoming chromatography mix；
D4, pharmaceutically common solid pharmaceutical preparation is made in the mixture after D3 steps are well mixed, is distributed into pouch bag
Dress, it is combined into the unit package of different size.
The solid pharmaceutical preparation is the formulations such as tablet, pill or capsule.
The present invention has advantages below compared with prior art：
The present invention adds Tibetan medicine processed product assistant too in mussot swertia herb effective part group, passes through reasonable compatibility, effectively drop
The low toxicity of mussot swertia herb effective part group.
Embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only part of the embodiment of the present invention, rather than whole embodiments.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
It is a kind of that there is the composition for reducing liver injury medicament toxicity, in its component comprising mussot swertia herb effective part group and
Help too, by weight ratio 1 part of mussot swertia herb effective part group, help too 0.1 part, the mussot swertia herb effective part group bag
Containing five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its mass ratio for (0.04~
0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
The preparation of described mussot swertia herb effective part group is using Chinese invention patent (CN2007101630978)
Method：
(1) Swertia mussotii medicinal material, crushing or segment are taken, with the 10-15 times of 0-95% measured ethanol water or aqueous acetone solution
Extraction three times, merges extract solution three times, is concentrated under reduced pressure, concentrate is carried out with petroleum ether, chloroform, ethyl acetate and n-butanol successively
Distribution, the distribution number of each organic solvent is 4 times, and each volume is concentrate initial volume.Each solvent distribution that is concentrated under reduced pressure is molten
Liquid, recycling design, obtain each solvent distribution position thick paste；
(2) n-butanol distribution position thick paste is dissolved with appropriate distilled water, is loaded onto the big of the resin material I that has pre-processed
Hole resin column upper end, after adsorbing 4-10 hours, eluted with 5-20BV distilled water with 0.5-2BV/h flow velocity.Then with 0.5-
2BV/h flow velocity linear gradient elution, eluent are 10-95% ethanol water, Fractional Collections eluent, merge 10-
40% ethanol water elutes liquid, is concentrated under reduced pressure into no alcohol taste；
(3) concentrate in step (2) is subjected to second of macroreticular resin post separation, concretely comprises the following steps and be loaded onto concentrate
Resin material II macroporous resin column upper end, 4-10 hours are adsorbed, eluted with distilled water with 0.5-3BV/h flow velocity, eluent
For 3-8BV, with 10-95% ethanol water linear gradient elutions, 10-30% ethanol waters elution liquid is collected, concentrates the receipts
Liquid collecting, it dry, pulverize and produce the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn into packet Swertia mussotii glycosides powder.Institute
It is river of the present invention that the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn, which is stated, into Swertia mussotii glycosides powder is grouped
Western Swertia patens effective part group.
A kind of preparation method with the composition for reducing liver injury medicament toxicity, comprises the following steps：
D1, assistant is taken first too, fine grinding；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning Bupleurum scorzonerifoliumWild effective part group and D1 step fine grindings after assistant too with bottoming chromatography mix；
D4, by the mixture direct packaging after D3 steps are well mixed into pouch-packaged, be combined into different size
Unit package.
Embodiment 2
It is a kind of that there is the composition for reducing liver injury medicament toxicity, in its component comprising mussot swertia herb effective part group and
Help too, by weight ratio 1 part of mussot swertia herb effective part group, help too 0.01 part, the mussot swertia herb effective part group
Comprising five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its mass ratio for (0.04~
0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
The preparation of described mussot swertia herb effective part group is using Chinese invention patent (CN2007101630978)
Method：
(1) Swertia mussotii medicinal material, crushing or segment are taken, with the 10-15 times of 0-95% measured ethanol water or aqueous acetone solution
Extraction three times, merges extract solution three times, is concentrated under reduced pressure, concentrate is carried out with petroleum ether, chloroform, ethyl acetate and n-butanol successively
Distribution, the distribution number of each organic solvent is 4 times, and each volume is concentrate initial volume.Each solvent distribution that is concentrated under reduced pressure is molten
Liquid, recycling design, obtain each solvent distribution position thick paste；
(2) n-butanol distribution position thick paste is dissolved with appropriate distilled water, is loaded onto the big of the resin material I that has pre-processed
Hole resin column upper end, after adsorbing 4-10 hours, eluted with 5-20BV distilled water with 0.5-2BV/h flow velocity.Then with 0.5-
2BV/h flow velocity linear gradient elution, eluent are 10-95% ethanol water, Fractional Collections eluent, merge 10-
40% ethanol water elutes liquid, is concentrated under reduced pressure into no alcohol taste；
(3) concentrate in step (2) is subjected to second of macroreticular resin post separation, concretely comprises the following steps and be loaded onto concentrate
Resin material II macroporous resin column upper end, 4-10 hours are adsorbed, eluted with distilled water with 0.5-3BV/h flow velocity, eluent
For 3-8BV, with 10-95% ethanol water linear gradient elutions, 10-30% ethanol waters elution liquid is collected, concentrates the receipts
Liquid collecting, it dry, pulverize and produce the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn into packet Swertia mussotii glycosides powder.Institute
It is river of the present invention that the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn, which is stated, into Swertia mussotii glycosides powder is grouped
Western Swertia patens effective part group.
A kind of preparation method with the composition for reducing liver injury medicament toxicity, comprises the following steps：
D1, assistant is taken first too, fine grinding；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning Bupleurum scorzonerifoliumWild effective part group and D1 step fine grindings after assistant too with bottoming chromatography mix；
D4, tablet is made with pharmaceutically conventional formulation method in the mixture after D3 steps are well mixed, be distributed into small
Bag packaging, it is combined into the unit package of different size.
Embodiment 3
It is a kind of that there is the composition for reducing liver injury medicament toxicity, in its component comprising mussot swertia herb effective part group and
Help too, by weight ratio 1 part of mussot swertia herb effective part group, help too 0.5 part, the mussot swertia herb effective part group bag
Containing five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its mass ratio for (0.04~
0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
The preparation of described mussot swertia herb effective part group is using Chinese invention patent (CN2007101630978)
Method：
(1) Swertia mussotii medicinal material, crushing or segment are taken, with the 10-15 times of 0-95% measured ethanol water or aqueous acetone solution
Extraction three times, merges extract solution three times, is concentrated under reduced pressure, concentrate is carried out with petroleum ether, chloroform, ethyl acetate and n-butanol successively
Distribution, the distribution number of each organic solvent is 4 times, and each volume is concentrate initial volume.Each solvent distribution that is concentrated under reduced pressure is molten
Liquid, recycling design, obtain each solvent distribution position thick paste；
(2) n-butanol distribution position thick paste is dissolved with appropriate distilled water, is loaded onto the big of the resin material I that has pre-processed
Hole resin column upper end, after adsorbing 4-10 hours, eluted with 5-20BV distilled water with 0.5-2BV/h flow velocity.Then with 0.5-
2BV/h flow velocity linear gradient elution, eluent are 10-95% ethanol water, Fractional Collections eluent, merge 10-
40% ethanol water elutes liquid, is concentrated under reduced pressure into no alcohol taste；
(3) concentrate in step (2) is subjected to second of macroreticular resin post separation, concretely comprises the following steps and be loaded onto concentrate
Resin material II macroporous resin column upper end, 4-10 hours are adsorbed, eluted with distilled water with 0.5-3BV/h flow velocity, eluent
For 3-8BV, with 10-95% ethanol water linear gradient elutions, 10-30% ethanol waters elution liquid is collected, concentrates the receipts
Liquid collecting, it dry, pulverize and produce the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn into packet Swertia mussotii glycosides powder.Institute
It is river of the present invention that the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn, which is stated, into Swertia mussotii glycosides powder is grouped
Western Swertia patens effective part group.
A kind of preparation method with the composition for reducing liver injury medicament toxicity, comprises the following steps：
D1, assistant is taken first too, fine grinding；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning Bupleurum scorzonerifoliumWild effective part group and D1 step fine grindings after assistant too with bottoming chromatography mix；
D4, pill is made with pharmaceutically conventional formulation method in the mixture after D3 steps are well mixed, be distributed into small
Bag packaging, it is combined into the unit package of different size.
Embodiment 4
It is a kind of that there is the composition for reducing liver injury medicament toxicity, in its component comprising mussot swertia herb effective part group and
Help too, by weight ratio 1 part of mussot swertia herb effective part group, help too 0.3 part, the mussot swertia herb effective part group bag
Containing five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its mass ratio for (0.04~
0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
The preparation of described mussot swertia herb effective part group is using Chinese invention patent (CN2007101630978)
Method：
(1) Swertia mussotii medicinal material, crushing or segment are taken, with the 10-15 times of 0-95% measured ethanol water or aqueous acetone solution
Extraction three times, merges extract solution three times, is concentrated under reduced pressure, concentrate is carried out with petroleum ether, chloroform, ethyl acetate and n-butanol successively
Distribution, the distribution number of each organic solvent is 4 times, and each volume is concentrate initial volume.Each solvent distribution that is concentrated under reduced pressure is molten
Liquid, recycling design, obtain each solvent distribution position thick paste；
(2) n-butanol distribution position thick paste is dissolved with appropriate distilled water, is loaded onto the big of the resin material I that has pre-processed
Hole resin column upper end, after adsorbing 4-10 hours, eluted with 5-20BV distilled water with 0.5-2BV/h flow velocity.Then with 0.5-
2BV/h flow velocity linear gradient elution, eluent are 10-95% ethanol water, Fractional Collections eluent, merge 10-
40% ethanol water elutes liquid, is concentrated under reduced pressure into no alcohol taste；
(3) concentrate in step (2) is subjected to second of macroreticular resin post separation, concretely comprises the following steps and be loaded onto concentrate
Resin material II macroporous resin column upper end, 4-10 hours are adsorbed, eluted with distilled water with 0.5-3BV/h flow velocity, eluent
For 3-8BV, with 10-95% ethanol water linear gradient elutions, 10-30% ethanol waters elution liquid is collected, concentrates the receipts
Liquid collecting, it dry, pulverize and produce the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn into packet Swertia mussotii glycosides powder.Institute
It is river of the present invention that the light yellow Swertia mussotii anti-hepatic fibrosis activity to fawn, which is stated, into Swertia mussotii glycosides powder is grouped
Western Swertia patens effective part group.
A kind of preparation method with the composition for reducing liver injury medicament toxicity, comprises the following steps：
D1, assistant is taken first too, fine grinding；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning Bupleurum scorzonerifoliumWild effective part group and D1 step fine grindings after assistant too with bottoming chromatography mix；
D4, capsule is made with pharmaceutically conventional formulation method in the mixture after D3 steps are well mixed, be distributed into
Pouch-packaged, it is combined into the unit package of different size.
Experimental example
Toxicity comparative experiments
SPF level KM mouse, male and female half and half, 20-24g；Purchased from Gansu Chinese of Traditional Chinese Medicine's Experimental Animal Center, the animal quality certification
Number：SYXK (sweet) 2015-0005.Purchased experimental animal is raised in 23 ± 2 DEG C of environment, and feeding standard experimental animal feed (is purchased from
Beijing Austria of section pulls together feed corporation,Ltd) and running water, animal adapt to conventional animal room after 2-3 days, tested.
Mussot swertia herb active component, 6 groups of Setup Experiments, after water 12h is can't help in fasting, disposable gastric infusion, K=
0.9, given low is respectively 12.3,11.1,9.97,8.98,8.08,7.27g/kg, observe and record 7 days animal dead feelings
Condition.As a result show, mussot swertia herb active component LD50 is 9.7g/kg；
Mussot swertia herb active component assistant too group, 6 groups of Setup Experiments, after water 12h is can't help in fasting, disposable gavage is given
Medicine, K=0.9, given low is respectively 13.7,12.3,11.1,9.97,8.98,8.08g/kg, observe and record 7 days animals
Death condition.As a result show, it is 10.6g/kg that mussot swertia herb active component assistant, which organizes very much LD50,.
As a result show：Assistant too compatibility can reduce the death rate of experimental animal, reduce mussot swertia herb effective part group
Toxicity.
Claims (5)
1. a kind of have the composition for reducing liver injury medicament toxicity, it is characterised in that described a kind of with reduction hepatic injury medicine
The pharmaceutical composition of thing toxicity, mussot swertia herb effective part group and Zuo Tai are included in its component.
A kind of 2. composition with reduction liver injury medicament toxicity according to claim 1, it is characterised in that its component
In include 1 part of mussot swertia herb effective part group by weight, assistant too 0.01-0.5 parts.
A kind of 3. composition for reducing liver injury medicament toxicity according to claim 1, it is characterised in that the western river deer in river
Tooth dish effective part group includes five kinds of Swertiamarin, gentiamarin, sweroside, mangiferin, Lutonaretin compositions, its quality
Than for (0.04~0.71)：(20~40)：(1~15)：(1.6~26)：(0.01~0.16).
4. according to a kind of preparation method of the composition of any described reduction liver injury medicament toxicity of claim 1-3, it is special
Sign is, comprises the following steps：
D1, assistant is taken first too, fine grinding, weighed by formula；
D2, weigh Bupleurum scorzonerifoliumWild effective part group；
D3, by proportioning by assistant Taihe county mussot swertia herb effective part group after D1 fine grindings with bottoming chromatography mix；
D4, pharmaceutically common solid pharmaceutical preparation is made in the mixture after D3 steps are well mixed, is distributed into pouch-packaged, then
It is combined into the unit package of different size.
A kind of 5. preparation method of composition for reducing liver injury medicament toxicity according to claim 4, it is characterised in that
The solid pharmaceutical preparation is tablet, pill or capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711081762.9A CN107875191A (en) | 2017-11-07 | 2017-11-07 | It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711081762.9A CN107875191A (en) | 2017-11-07 | 2017-11-07 | It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107875191A true CN107875191A (en) | 2018-04-06 |
Family
ID=61779140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711081762.9A Pending CN107875191A (en) | 2017-11-07 | 2017-11-07 | It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107875191A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202747A (en) * | 2020-03-23 | 2020-05-29 | 中国科学院西北高原生物研究所 | Application of zotara in preparation of medicine for promoting MS275 to pass through blood brain barrier |
| CN116098932A (en) * | 2022-12-26 | 2023-05-12 | 重庆三峡医药高等专科学校 | Swertia pseudochinensis extract for improving cholestatic liver injury and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695717A (en) * | 2005-05-25 | 2005-11-16 | 泽仁呷 | Combination of medication for treating hepatic disease, preparation method and application |
| CN101396428A (en) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | Tibetan capillary extract and preparation method, medicine composition and use thereof |
| CN104971088A (en) * | 2014-04-11 | 2015-10-14 | 中央民族大学 | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof |
-
2017
- 2017-11-07 CN CN201711081762.9A patent/CN107875191A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1695717A (en) * | 2005-05-25 | 2005-11-16 | 泽仁呷 | Combination of medication for treating hepatic disease, preparation method and application |
| CN101396428A (en) * | 2007-09-30 | 2009-04-01 | 中国科学院西北高原生物研究所 | Tibetan capillary extract and preparation method, medicine composition and use thereof |
| CN104971088A (en) * | 2014-04-11 | 2015-10-14 | 中央民族大学 | Tibetan artemisia capillaris extract and preparation method, drug composition and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 于智敏: "《中医药之"毒"》", 31 March 2007, 科学技术文献出版社 * |
| 杨红霞: "川西獐牙菜毒性及其机制研究", 《中国科学院机构知识库网格》 * |
| 高天爱等: "《矿物药真伪图鉴及应用》", 28 February 2012, 山西科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111202747A (en) * | 2020-03-23 | 2020-05-29 | 中国科学院西北高原生物研究所 | Application of zotara in preparation of medicine for promoting MS275 to pass through blood brain barrier |
| CN116098932A (en) * | 2022-12-26 | 2023-05-12 | 重庆三峡医药高等专科学校 | Swertia pseudochinensis extract for improving cholestatic liver injury and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010034971A2 (en) | Sub-critical water extraction of medicinal plants | |
| KR101972083B1 (en) | The Black Ginseng extract including alcoholic liver injury prevention functional ingredients and method for manufacturing it | |
| GB2463531A (en) | The extraction of pharmacological agents from medicinal herbs using subcritical water | |
| CN106420902A (en) | Hepatoprotective activity and new medical application of glycyrrhiza inflata extract and licochalcone A | |
| Wang et al. | Phytochemical information and biological activities of quinolizidine alkaloids in Sophora: a comprehensive review | |
| CN101579375B (en) | Extract of bupleurum, preparation method and application thereof | |
| CN102058632A (en) | Application of medicinal composition to preparation of medicament for preventing and treating alcoholic liver damage and fatty liver and lowering blood fat | |
| JP6605036B2 (en) | Method for preparing a medicinal composition for preventing or treating liver and kidney damage-related diseases | |
| CN107875191A (en) | It is a kind of that there is composition for reducing liver injury medicament toxicity and preparation method thereof | |
| CN107929337A (en) | A kind of preparation method and application of Panax stipuleanatus Tsai et Feng anti-inflammatory active component | |
| CN104815138A (en) | Immature bitter orange extract, preparation and application | |
| CN102134268A (en) | Method for preparing panax japonicus saponin IVa and application of panax japonicus saponin IVa in preparing a medicament for protecting liver and lowering transaminase | |
| CN106176716A (en) | The new application of daphane diterpene compound pimelotide C | |
| Bai et al. | Advances in the chemical constituents, pharmacological properties and clinical applications of TCM formula Yupingfeng San | |
| US10953060B2 (en) | Method for extraction of Chinese herbal medicine using small molecule micro-shear technology | |
| CN102133220A (en) | Preparation method of pulsatilla saponin matter as well as preparation method of preparation thereof and application of pulsatilla saponin matter in preparing medicaments for treating cancers | |
| CN106074588A (en) | The combination of Rhizoma Paridis forrestii monomer saponin and pharmaceutical composition and its application in pharmacy | |
| CN112062738B (en) | Artemisinol A-B, pharmaceutical composition thereof, and preparation method and application thereof | |
| CN107737160B (en) | Xiaoaiping dropping pill containing medicinal composition of marsdenia tenacissima and preparation method thereof | |
| CN107446014A (en) | The Dulong Paris polyphylla ethanol extract and its application in pharmacy is separated with its chemical composition and authentication method | |
| CN104095832B (en) | A kind of preventing and treating hepatic fibrosis medicines and preparation method thereof | |
| CN102204960A (en) | Chinese medicinal composition for treating hepatopathy and preparation method thereof | |
| US20100168451A1 (en) | Preparative method of dihydrocucurbitacin f-25-o-acetate and the use thereof in the manufacture of medicaments for treating cancers | |
| CN105106254A (en) | Anti-influenza loosestrife extract | |
| CN104840496B (en) | A kind of bupleurum root dropping pills and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180406 |
|
| RJ01 | Rejection of invention patent application after publication |